Business Description
IDEAYA Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US45166A1025
Total Employee Number:
145Description
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.47 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.16 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 22.11 | |||||
Beneish M-Score | 25.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26.2 | |||||
3-Year EBITDA Growth Rate | -7.1 | |||||
3-Year EPS without NRI Growth Rate | 3.4 | |||||
3-Year FCF Growth Rate | 27.6 | |||||
3-Year Book Growth Rate | 17.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.92 | |||||
9-Day RSI | 54.29 | |||||
14-Day RSI | 57.85 | |||||
3-1 Month Momentum % | -8.05 | |||||
6-1 Month Momentum % | -21.35 | |||||
12-1 Month Momentum % | 31.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.74 | |||||
Quick Ratio | 10.74 | |||||
Cash Ratio | 10.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.1 | |||||
Shareholder Yield % | -0.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -81.44 | |||||
Net Margin % | -62.17 | |||||
EBITDA Margin % | -79.4 | |||||
FCF Margin % | -40.12 | |||||
OCF Margin % | -39.21 | |||||
ROE % | -13.91 | |||||
ROA % | -12.81 | |||||
ROIC % | -48.03 | |||||
3-Year ROIIC % | -23.33 | |||||
ROC (Joel Greenblatt) % | -572.34 | |||||
ROCE % | -17.74 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 14.57 | |||||
PB Ratio | 3.43 | |||||
Price-to-Tangible-Book | 3.43 | |||||
EV-to-EBIT | -15.72 | |||||
EV-to-Forward-EBIT | 14.26 | |||||
EV-to-EBITDA | -16.13 | |||||
EV-to-Revenue | 12.81 | |||||
EV-to-Forward-Revenue | 432.58 | |||||
EV-to-FCF | -32.81 | |||||
Price-to-GF-Value | 0.19 | |||||
| Price-to-Net-Current-Asset-Value | 5.34 | |||||
| Price-to-Net-Cash | 5.56 | |||||
Earnings Yield (Greenblatt) % | -6.36 | |||||
FCF Yield % | -2.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IDEAYA Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 192.037 | ||
| EPS (TTM) (€) | -1.393 | ||
| Beta | -0.0792 | ||
| 3-Year Sharpe Ratio | 0.48 | ||
| 3-Year Sortino Ratio | 0.88 | ||
| Volatility % | 42.68 | ||
| 14-Day RSI | 57.85 | ||
| 14-Day ATR (€) | 1.200635 | ||
| 20-Day SMA (€) | 31.257 | ||
| 12-1 Month Momentum % | 31.63 | ||
| 52-Week Range (€) | 17.9 - 35.43 | ||
| Shares Outstanding (Mil) | 96.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IDEAYA Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IDEAYA Biosciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 112 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 21 days | ||
| General meeting for 2026 | 2026-06-16 13:30 | 25.98 (+4.13%) | ||
| Guidance call for 2026 | 2026-06-04 08:45 | 24.34 (+2.53%) | ||
| Guidance call for 2026 | 2026-06-03 07:35 | 23.87 (-2.65%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 24.60 (+3.06%) | ||
| IDEAYA Biosciences Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma | 2026-04-13 08:00 | 25.91 (-1.30%) | ||
| IDEAYA Biosciences\' Virtual Fireside Chat hosted by Umer Raffat of Evercore ISI | 2026-02-23 12:00 | 27.00 (-2.88%) | ||
| Guidance call for 2026 | 2026-02-18 13:00 | 26.00 (+2.36%) | ||
| Annual report for 2025 | 2026-02-17 | 25.40 (+0.00%) |
Show
Entries
IDEAYA Biosciences Inc Frequently Asked Questions
What is IDEAYA Biosciences Inc(STU:30J)'s stock price today?
The current price of STU:30J is €32.06. The 52 week high of STU:30J is €35.43 and 52 week low is €17.90.
When is next earnings date of IDEAYA Biosciences Inc(STU:30J)?
The next earnings date of IDEAYA Biosciences Inc(STU:30J) is 2026-08-05 Est..
Does IDEAYA Biosciences Inc(STU:30J) pay dividends? If so, how much?
IDEAYA Biosciences Inc(STU:30J) does not pay dividend.
Press Release
Articles on IDEAYA Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers